Table 2.
Incidence of drug-related treatment-emergent adverse events and biochemical toxicities occurring at any point during the study
| Any grade | Grade 3 or 4 | |
|---|---|---|
| n (%) | n (%) | |
| Hematologic adverse events | ||
| Anemia | 6 (40) | 1 (7) |
| Lymphopenia | 5 (33) | 4 (27) |
| Leukopenia | 4 (27) | 1 (7) |
| Thrombocytopenia | 4 (27) | 0 |
| Nonhematologic adverse events | ||
| Hand–foot skin reaction | 10 (67) | 2 (13) |
| Diarrhea | 10 (67) | 1 (7) |
| Hypophosphatemia | 8 (53) | 4 (27) |
| AST elevation | 8 (53) | 2 (13) |
| ALT elevation | 7 (47) | 2 (13) |
| Proteinuria | 7 (47) | 1 (7) |
| Hypoalbuminemia | 7 (47) | 0 |
| Lactate dehydrogenase elevation | 7 (47) | 0 |
| Alopecia | 6 (40) | 0 |
| Weight loss | 6 (40) | 0 |
| Anorexia | 5 (33) | 0 |
| Constipation | 5 (33) | 0 |
| Fatigue | 5 (33) | 0 |
| Hypertension | 5 (33) | 0 |
| Voice changes | 5 (33) | 0 |
| Rash/desquamation | 4 (27) | 0 |
| Biochemical toxicitiesa | ||
| ALP elevation | 14 (93) | 2 (13) |
| Hypoalbuminemia | 14 (93) | 0 |
| AST elevation | 13 (87) | 3 (20) |
| ALT elevation | 12 (80) | 3 (20) |
| Hypophosphatemia | 12 (80) | 4 (27) |
| Proteinuria | 12 (8) | 1 (7) |
| Hypocalcemia | 9 (60) | 0 |
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase
aBiochemical toxicities that occurred at any time after the start of study treatment, including those not reported as adverse events or being related to study drug